Will any of the jobs that exist today still be around in 20 years? Fast Future’s Steve Wells, Alexandra Whittington and Rohit Talwar explore whether automation is destined to rewrite all our futures.
Continue reading “Will artificial intelligence mean the end of jobs?” »
Why are we often so wrong about how the future and future technology will reshape society and our personal lives? In this new video from the Galactic Public Archives, Futurist Gray Scott tells us why he thinks it is important to look at all aspects of the future.
Follow us on social media:
Twitter / Facebook / Instagram
Continue reading “Futurist Gray Scott: We Can’t Ignore Our Psychological Future” »
The future of cancer care should mean more cost-effective treatments, a greater focus on prevention, and a new mindset: A Surgical Oncologist’s take
Multidisciplinary team management of many types of cancer has led to significant improvements in median and overall survival. Unfortunately, there are still other cancers which we have impacted little. In patients with pancreatic adenocarcinoma and hepatocellular cancer, we have been able to improve median survival only by a matter of a few months, and at a cost of toxicity associated with the treatments. From the point of view of a surgical oncologist, I believe there will be rapid advances over the next several decades.
Robotic Surgery
There is already one surgery robot system on the market and another will soon be available. The advances in robotics and imaging have allowed for improved 3-dimensional spacial recognition of anatomy, and the range of movement of instruments will continue to improve. Real-time haptic feedback may become possible with enhanced neural network systems. It is already possible to perform some operations with greater facility, such as very low sphincter-sparing operations for rectal adenocarcinoma in patients who previously would have required a permanent colostomy. As surgeons’ ability and experience with new robotic equipment becomes greater, the number and types of operation performed will increase and patient recovery time, length of hospital stay, and return to full functional status will improve. Competition may drive down the exorbitant cost of current equipment.
Artificial Intelligence (AI) represents both the biggest opportunity and potentially the greatest threat to the legal profession in history.
This is part of a bigger global revolution – where society, business and government are likely to experience more change in the next 20–30 years than in the last 500.
This large-scale disruption is being driven by the combined effects of AI and other disruptive technologies whose speed, power and capability are growing exponentially – or faster.
The automotive industry is undergoing a period of rapid and radical transformation fueled by a range of technological innovations, digital advancements and wave after wave of new entrants and alternative business models; as a result, the entire sector is seeing major disruption.
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.
“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
“Two Tesla Motors veterans want to build a European counterpart to Elon Musk’s “gigafactory”, in an effort to stake out a dominant position in the fast-evolving supply chain for makers of electric vehicles.”
Superlubricity nano-structured self-assembling coating repairs surface wear, decreases emissions and increases HP and gas mileage.
Globally about 15 percent of manmade carbon dioxide comes from vehicles. In more developed countries, cars, trucks, airplanes, ships and other vehicles account for a third of emissions related to climate change. Emissions standards are fueling the lubricant additives market with innovation.
Up to 33% of fuel energy in vehicles is used to overcome friction. Tribology is the science of interacting surfaces in relative motion inclusive of friction, wear and lubrication. This is where TriboTEX, a nanotechnology startup is changing the game of friction modification and wear resilience with a lubricant additive that forms a nano-structured coating on metal alloys.
This nano-structured coating increases operating efficiency and component longevity. It is comprised of synthetic magnesium silicon hydroxide nanoparticles that self-assemble as an ultralow friction layer, 1/10 of the original friction resistance. The coating is self-repairing during operation, environmentally inert and extracts carbon from the oil. The carbon diamond-like nano-particle lowers the friction budget of the motor, improving fuel economy and emissions in parallel while increasing the power and longevity of the motor.
TriboTEX has a Kickstarter campaign that has just surpassed $100,000 in funding. The early bird round has just closed that offered the product at one half the cost of its retail. The final round offers the lubricant system self-forming coating at 75 percent and is ending shortly. The founder Dr. Pavlo Rudenko, Ph.D. is a graduate of Singularity University GSP11 program.
I use to hate it when my dad insisted that I read something longer than 2 paragraphs. (Something related to his interests, but not to my school work, his career or our family). That’s because it shouldn’t require a 30 minute read to determine if it piques my interest, as it does his.
But I am asking Lifeboat readers to invest 37 minutes in the video linked below. Even if you give it just 5 minutes, it will provide sufficient motive for you to stick around until the end. [continue below video]
I want you view it because we are on the threshold of something bigger than many people realize. Bitcoin and the blockchain is not just a new currency or a way of distributing books among network users. We are becoming involved with a radical experiment in applied game theory that is shockingly simple, but nascent. Opportunities abound, and the individuals who recognize those opportunities or learn to exploit them will benefit themselves as they benefit the global community. Because it is so radical (and because it clashes with deeply ingrained beliefs about authority, control mechanisms, democracy and money), it seems complex and risky—but it’s really not.
Continue reading “Antonopolous Clarifies Blockchain’s Profound Leap” »
Orginal press: http://www.prweb.com/releases/2017/02/prweb14062199.htm
Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel biologics for complex regeneration and disease reversion, and SC21 Biotech, (http://www.sc21bio.tech), a biotechnology company focused on translational therapeutic applications of autologous stem cell therapy, have announced a collaboration to focus on novel cellular reprogramming and production approaches for CCR5 Delta32 homozygous cord blood stem cells, for long-term control of HIV via transplantation.
“We are very excited about this collaboration with SC21 Biotech,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular reprogramming tools and SC21 Biotech’s translational cell therapy experience, will make for a transformational opportunity in this area of HIV disease control.”
I use to hate it when my dad insisted that I read something longer than 2 paragraphs. (Something related to his interests, but not to my school work, his career or our family). That’s because it shouldn’t require a 30 minute read to determine if it piques my interest, as it does his.
